Spartan Wealth Advisory Services LLC Takes $603,000 Position in Kestra Medical Technologies, Ltd. $KMTS

Spartan Wealth Advisory Services LLC purchased a new position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 30,268 shares of the company’s stock, valued at approximately $603,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its holdings in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. boosted its holdings in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares during the last quarter. Rhumbline Advisers boosted its holdings in Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after buying an additional 874 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter worth about $31,000. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in shares of Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after acquiring an additional 1,392 shares during the last quarter.

Insider Activity at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider directly owned 395,467 shares in the company, valued at $8,229,668.27. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

KMTS has been the topic of a number of analyst reports. The Goldman Sachs Group cut their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. BTIG Research upped their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Finally, Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kestra Medical Technologies has an average rating of “Hold” and a consensus price target of $27.83.

Kestra Medical Technologies Stock Performance

NASDAQ:KMTS opened at $24.42 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The business’s 50-day simple moving average is $22.28 and its 200-day simple moving average is $22.69. Kestra Medical Technologies, Ltd. has a fifty-two week low of $14.10 and a fifty-two week high of $30.00. The stock has a market capitalization of $1.43 billion, a PE ratio of -10.09 and a beta of 0.47.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. Sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.3 earnings per share for the current fiscal year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.